Open an account

AstraZeneca

AZN · LONDON

$171.49−$1.08 (−0.63%)TodayMarket closed ·
Prev close $172.57

About AZN

AstraZeneca Plc is a global, science-led biopharmaceutical company focused on the discovery, development, and commercialization of prescription medicines. The firm focuses on the discovery, development, and commercialization of prescription medicines. The firm operates across therapy areas, including Oncology; Cardiovascular, Renal and Metabolism (CVRM); Respiratory and Immunology (R&I); Vaccines and Immune Therapies (V&I), and Rare Disease. In the Oncology area, its key products include Tagrisso, Imfinzi, Calquence, Lynparza, and Enhertu. The key products of CVRM area include Farxiga/Forxiga, Brilinta/Brilique, Crestor, and Lokelma. In the R&I area, the key products are Symbicort, Fasenra, Breztri/Trixeo, and Tezspire. In the V&I Therapies area, the products are Beyfortus and FluMist. The products in the Rare Disease area are Ultomiris, Soliris, Strensiq, and Koselugo. The company has about 191 projects in its development pipeline, including 19 new molecular entities (NMEs) in the late-stage pipeline. The firm distributes its products in over 125 countries.

Employees
96,100
Headquarters
CAMBRIDGE, Cambridgeshire
Listed
Sep 21, 2007
Sector
Health Care
Industry
Pharmaceuticals
Website
astrazeneca.com

AZN key statistics

Market cap
201.31B
Price-earnings ratio
25.83
Dividend yield
1.87%
Average volume
2.92M
Volume
3.69M
Open price
$171.17
High today
$171.75
Low today
$169.51
52 Week high
$212.71
52 Week low
$153.41

AstraZeneca (AZN) at a glance

AstraZeneca (AZN) last traded at $171.49, with a market cap of 201.31B, a price-to-earnings ratio of 25.83 and a dividend yield of 1.87%.

Today the stock has traded between $169.51 and $171.75. The current price is 1.2% above the day's low and 0.2% below its high.

Volume so far is 3.69M shares, above the average of 2.92M shares a day.

Over the past year AstraZeneca has ranged from $153.41 to $212.71, and now sits 30% of the way up that range.

AstraZeneca met or beat analyst EPS estimates in 4 of the last 8 quarters. In Q2 FY26 it reported $2.63 per share against an estimate of $2.55.

The average analyst price target is $209.53, 22.2% above the current price, from 2 recent ratings.

Analyst ratings

Latest rating from each analyst over the past 12 months

100%of 2 analyst ratings say Buy
  • Buy100.0%
  • Hold0.0%
  • Sell0.0%
Price target · 28 analystsAvg $209.53
Low
$89.19
Now
$171.49
High
$277.63

AZN earnings

Earnings per share, reported against the analyst estimate

Beat the estimate in 4 of the last 8 quarters, by 3.6% on average.

  1. Q3 FY24: reported $2.08 per share against an estimate of $2.07
  2. Q4 FY24: reported $2.09 per share against an estimate of $2.10
  3. Q1 FY25: reported $2.49 per share against an estimate of $2.28
  4. Q2 FY25: reported $2.17 per share against an estimate of $2.21
  5. Q3 FY25: reported $2.38 per share against an estimate of $2.35
  6. Q4 FY25: reported $2.12 per share against an estimate of $2.15
  7. Q1 FY26: reported $2.58 per share against an estimate of $2.59
  8. Q2 FY26: reported $2.63 per share against an estimate of $2.55

AZN news

  • Vandana Singh

    FDA Conditionally Approves AstraZeneca's Rare Kidney Disease Drug

  • Press releaseBusiness Wire

    ZEGFROVY® (sunvozertinib) now available in the US for patients with previously treated non-small cell lung cancer with EGFR exon 20 insertion mutations

  • Vandana Singh

    AstraZeneca/Amgen Drug Shows Significant Remission in Eosinophilic Esophagitis Study

  • Press releaseBusiness Wire

    TEZSPIRE positive results from Phase III CROSSING trial in eosinophilic esophagitis including symptom improvement, histologic and endoscopic remission presented at United European Gastroenterology Week

  • Akanksha Bakshi

    Oracle Joins Forces With AstraZeneca to Put AI to Work in Drug Research

  • Vandana Singh

    Novavax's Second-Largest Shareholder Sells $32.6 Million in Stock, Ends Activist Push

  • Press releaseBusiness Wire

    AstraZeneca to present overall survival data from four pivotal Phase III trials in Presidential Symposia at ESMO 2026 featuring Sone-Ve, IMFINZI® (durvalumab), TAGRISSO® (osimertinib) and savolitinib

  • Vandana Singh

    AstraZeneca Turns to AI to Crack Tough Heart and Liver Diseases in Billion-Dollar Deal

Most active stocks

Highest trading volume today

Newly listed

Companies that went public in the past six weeks

Information on this page is provided for informational purposes only and is not a recommendation to buy, sell or hold any security. Investing involves risk, including possible loss of principal. Market data is delayed at least 15 minutes and is provided without warranty. Analyst ratings, price targets and company data come from third-party sources. Past performance does not guarantee future results.